Scantox Unveils Enhanced DuplexSeq™ Platform with Cloud-Based Mutagenesis Application

Scantox Enhances DuplexSeq™ Platform with New Cloud-Based Mutagenesis Application

On May 12, 2026, Scantox Group announced a significant upgrade to its bioinformatics capabilities by unveiling the Scantox DuplexSeq Mutagenesis application. This cutting-edge application is hosted on a newly enhanced bioinformatics platform specifically designed to elevate the functionality and availability of its DuplexSeq™ mutation assays and reagents.

Matt Tate, PhD, Scantox's Director of Business Development, expressed enthusiasm for the new platform, stating, "The DuplexSeq™ platform is now faster and more accessible, primed to meet the increasing demands of error-corrected sequencing in genomic security. By having Clint Valentine, the original architect of the DuplexSeq™ range, lead this transition, we ensure our clients have full confidence in the enhanced platform. DuplexSeq™ stands out as the premier methodology for non-clinical mutation evaluation, and now it's ready for larger-scale implementation."

Scantox's DuplexSeq™ has been meticulously designed to combine scientific rigor and computational strength. Clint Valentine, now the Vice President of Operations at Fulcrum Genomics, commented on the migration process to the LatchBio platform, highlighting its seamless nature. "The initial DuplexSeq™ suite was created with stringent scientific standards and computational robustness in mind. Transitioning to LatchBio was straightforward. Tests conducted with the original TwinStrand validation dataset confirmed that the results remain consistent while enhancing the platform's capabilities. The science remains unchanged, but the user experience is significantly improved."

Scantox chose LatchBio as its bioinformatics foundation after thorough evaluations of numerous platforms. This choice was driven by LatchBio's user-friendly interface and suitability for regulated non-clinical scientific research. The Scantox DuplexSeq Mutagenesis application enables one-click execution of the validated workflow for mutation analysis. It centralizes data and project management, offers improved data visualization, and generates tailored reports for various sponsors. Moreover, existing clients can easily upload historical data from previous studies directly to the new platform. They will receive guidance throughout the integration process.

Kyle Giffin, the Director of Operations at LatchBio, emphasized the critical nature of data integrity, traceability, and audit-readiness for DuplexSeq™ clients, stating, "LatchBio was engineered to meet these essential regulatory standards with 21 CFR Part 11 controls, immutable audit logs, and SOC 2 Type II certified infrastructure."

The revamped DuplexSeq™ reagents are presently available, with further commercial availability expected by the third quarter of 2026. Scantox will hold a live webinar to assist clients in transitioning to the new platform; registration details can be found at their official website.

About Scantox

Scantox is an integrated preclinical Contract Research Organization (CRO) that supports sponsors from discovery to the preclinical development stage leading to IND submission. With operations in Denmark, Sweden, Austria, and the United Kingdom, Scantox blends discovery, regulatory toxicology, pharmaceutical, and analytical development along with genetic toxicology on a coordinated platform. This dedication to quality ensures customers generate high-quality data ready for regulatory bodies, while also adhering to timelines across all disciplines. A recognized leader in CNS pharmacology and Göttingen minipig research, Scantox also showcases advanced capabilities in genetic toxicology and genomic safety, including Big Blue® transgenic rodent assays and DuplexSeq™ testing. Founded in 1977, Scantox operates under the ownership of Impilo, the leading Nordic healthcare investment firm. More information is available at Scantox's website.

About LatchBio

LatchBio, based in San Francisco, is at the forefront of developing data infrastructure and workflow solutions tailored for the biotechnology sector. By empowering kit, assay, and instrument providers, LatchBio focuses on delivering customer-oriented bioinformatics platforms fortified with enterprise-level security, compliance with 21 CFR Part 11, and SOC 2 Type II certified infrastructure. More details can be found at LatchBio's website.

About Fulcrum Genomics

Specializing in bioinformatics consulting and software development for the genomics industry, Fulcrum Genomics collaborates with biotechnological and pharmaceutical companies to create and maintain enterprise-grade bioinformatics systems. Founded by leaders in genomics and computational biology, they are committed to advancing scientific research. Discover more at Fulcrum Genomics’ website.